Salute e Benessere

Curve Therapeutics strengthens Leadership Team with appointment of experienced…

Simon Kerry, Chief Executive Officer of Curve Therapeutics, commented: "Simon brings extensive financial experience at the leadership level from multiple clinical stage biotech companies. His appointment comes at a pivotal time as we look to expand our team, advance our proprietary Microcycle® discovery platform, and progress our pipeline of potential first-in-class assets." Simon Kerry, Chief Executive Officer of Curve Therapeutics, commented: "Simon brings extensive financial…

Bruin Biometrics Announces PIPPA, The Only Medical Pressure Injury Technology To…

PIPPA is designed to integrate seamlessly with existing Electronic Medical Records, providing real-time data and analytics to healthcare providers. It automates the production of the SPIPP checklist, developed by NPIAP, ensuring high fidelity data collection and ease of use. This integration supports consistent and comprehensive application of the SPIPP checklist, helping to reduce the incidence of HAPIs and improve patient care. PIPPA is designed to integrate seamlessly with existing...

Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT

Comment by Mark Crossley, CEO of Indivior PLC"Despite positive early performance trends at the start of the second quarter, SUBLOCADE net revenue (NR) has continued to be impacted more than we expected by a combination of transitory factors, primarily the elimination of COVID emergency measures related to automatic Medicaid coverage renewals. Furthermore, as we look to the second half of the year, the U.S. government has extended renewal allowances for certain States which will further…

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate…

The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.Munich, Germany, July 9, 2024 –SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera...

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution…

The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate 1real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur.The solution is set to launch in selected European markets in the coming months.Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY)...

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on…

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney DiseaseHalle (Saale) / Munich, Germany, July 9, 2024- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will host an R&D update conference call and webcast on...

Io Therapeutics, Inc., announces presentation of data on induction of tumor…

The presented studies showed that oral treatment with IRX5010 resulted in suppression of growth in mouse models of each of five types of the most prevalent and deadly cancers in humans, i.e. triple negative breast, Her-2 positive breast, non-small cell lung, colorectal, and prostate cancers. In all five models, treatment with IRX5010 induced tumor infiltrating effector memory phenotype T-lymphocytes associated with reduction in tumor growth. Treatment with IRX5010 did not directly impact...

Eli Lilly's Donanemab Approval Heats Up Alzheimer's Disease Treatment Market |…

As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Alzheimer's disease in the 7MM were 15.4 million. These cases are projected to increase further during the forecast period (2024–2034). As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Alzheimer's disease in the 7MM were15.4 million. These cases are projected to increase further during the forecast period (2024–2034). In 2023,the United Stateshad the highest proportion of...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationMontrouge, France, July 8, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2024: 303,744 DBV...

Boehringer Ingelheim produces its own green energy

German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plantIngelheim site can cover 95% of its energy needs from renewable sourcesNew power plant helps achieve the company's global climate targets and saves around 50,000 tons of CO 2per year Boehringer Ingelheim inaugurated a biomass power plant at its Ingelheim site on Monday. With the new power plant, Boehringer Ingelheim is optimizing its energy supply and protecting the environment at...

Oxurion signs a Letter of Intent and enters into exclusive negotiations to…

Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell productionLEUVEN, BELGIUM - July 8, 2024 – 6:30 pm,OxurionNV(Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces that it has signed a Letter of Intent (LOI) to enter into exclusive negotiations with a view to, subject to certain conditions, acquiring an 80% majority stake in a CRO(Contract Research Organisation)...

Half-year statement of IPSEN liquidity agreement - 2024 06 30

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF PARIS, FRANCE, July 8, 2024- Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2024, the following resources were included to the dedicated liquidity account: 34,591 shares€1,418,034.45It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account: 12,751 shares€3,137,934.80 Between January 1 st,...

Casino Group: Renewal of partnership with Sherpa

Press release 8 July 2024 The Sherpa Cooperative and Casino renew their partnership to supply 119 Sherpa storesCasino and the Sherpa Cooperative announced today that they have renewed their partnership. Casino will continue to supply the 119 food stores in the Sherpa network, which is the retail benchmark in mountain regions. This renewal is a continuation of the partnership that has linked the two brands since 2009. The supply contract includes providing cooperative members...

Roche to reintroduce Susvimo in the US for people with neovascular age-related…

The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections that are standard of care for nAMD, which impacts 20 million people worldwide and can cause blindness if left untreatedBy continuously delivering medicine to the eye through a refillable implant, Susvimo is the first and only approved nAMD treatment shown to maintain vision with two refills a...

DNA Diagnostics Market Set to Reach USD 21.2 Billion by 2029, Driven by…

Browse in-depth TOC on "DNA Diagnostics Market". Browse in-depth TOC on "DNA Diagnostics Market". 350 - Tables48 - Figures347 - Pages Market Leadership and Strategy Illumina Inc. leads the DNA diagnostics market, leveraging its expertise in sequencing and array-based solutions for genetic analysis. The company's integrated systems, consumables, and informatics platforms support comprehensive genetic analysis and are pivotal in maintaining its market dominance....

IVD Reagents Market to be Worth $79.76 Billion by 2031 - Exclusive Report by…

In-vitro diagnostic (IVD) reagents include oligonucleotides, antibodies, nucleic acid probes, purified proteins or peptides, buffers, calibrators, serum, cell medium, and standards & controls used in research activities. These reagents are used to diagnose and prevent diseases or other conditions and manufacture IVD kits & assays for diagnostic purposes. In-vitro diagnostic (IVD) reagents include oligonucleotides, antibodies, nucleic acid probes, purified proteins or peptides…

Rising Hypertension Rates Boost Blood Pressure Cuffs Market Revenue, Projected…

Increasing awareness about the importance of regular blood pressure monitoring for maintaining overall health is driving market growth. With a growing elderly population worldwide, there is a higher prevalence of hypertension and other cardiovascular diseases, leading to increased demand for blood pressure monitoring devices. Increasing awareness about the importance of regular blood pressure monitoring for maintaining overall health is driving market growth. With a growing elderly population...

Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions…

Incorporating blood glucose monitoring into compact and portable smart wearable devices is becoming a major trend. The application provides real-time, convenient, and accurate data reports and health guidance for people monitoring their blood sugar levels. According to a recent report by Grand View Research, the global CGM device market size was approximately $4.6 billion in 2023, with an expected compound annual growth rate of 7.19% from 2024 to 2030. Targeting this emerging market, Goodix…

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 08 July 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™…

UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025Strategic partnership with Cencora (formerly AmerisourceBergen) to support the planned commercial launches of LYTENAVA in UK and EU ISELIN, N.J., July08, 2024(GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc...

Buyback of Class B shares in Essity during week 27, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...

Orexo: invitation to presentation of the Q2 2024 Interim Report

When registered you will be provided phone numbers and a conference ID to access the conference. When registered you will be provided phone numbers and a conference ID to access the conference. To attend via webcast: https://ir.financialhearings.com/orexo-q2-report-2024 Prior to the event the presentation material will be available on the website under Investors/Reports, Presentations. Contact: Lena Wange, IR & Communications Directorir@orexo.com+46 (0)18 780 88 00 ...

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning…

“Dosing the first patient in the GALAXIES Lung-301 study marks a significant milestone for belrestotug + dostarlimab. iTeos was founded with the goal of advancing therapeutic options for patients by leveraging best-in-class science. The decision to launch our first TIGIT:PD-1 doublet Phase 3 trial underscores our disciplined, data-driven investment approach and was informed by several promising preliminary clinical surrogates such as safety, ORR, and depth of response from the latest...

Cambrex to Expand Stability Storage Business with New Facility in Durham, North…

Tom Loewald, CEO at Cambrex, stated, "We are thrilled to expand Q1 Scientific's reach into Durham, North Carolina, enhancing our ability to serve pharmaceutical companies across North America. This investment not only broadens our footprint but also leverages Q1 Scientific's extensive expertise in the stability storage business." Tom Loewald, CEO at Cambrex, stated, "We are thrilled to expand Q1 Scientific's reach intoDurham, North Carolina, enhancing our ability to serve…

Altri Comunicati